AAMU
ALXN

Amundi Asset Management US’s Alexion Pharmaceuticals ALXN Stock Holding History

Amundi Asset Management US’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$69.5M Sell
454,408
-906,090
-67% -$140M 0.05% 344
2020
Q4 		$213M Buy
1,360,498
+70,180
+5% +$9.02M 0.18% 124
2020
Q3 		$148M Buy
1,290,318
+64,897
+5% +$7M 0.15% 141
2020
Q2 		$138M Buy
1,225,421
+516,321
+73% +$54.8M 0.16% 126
2020
Q1 		$63.7M Sell
709,100
-54,424
-7% -$5.34M 0.11% 179
2019
Q4 		$82.6M Buy
763,524
+268,839
+54% +$28.8M 0.1% 207
2019
Q3 		$48.4M Sell
494,685
-80,710
-14% -$9.1M 0.07% 291
2019
Q2 		$75.4M Sell
575,395
-235,972
-29% -$30.4M 0.06% 234
2019
Q1 		$110M Buy
811,367
+110,593
+16% +$13.8M 0.15% 144
2018
Q4 		$68.2K Buy
700,774
+176,005
+34% +$20.8M 0.06% 206
2018
Q3 		$72.9M Buy
524,769
+27,041
+5% +$3.39M 0.1% 220
2018
Q2 		$61.8M Sell
497,728
-479,573
-49% -$56M 0.09% 235
2018
Q1 		$109M Sell
977,301
-477,197
-33% -$57M 0.17% 142
2017
Q4 		$174M Buy
1,454,498
+1,377,388
+1,786% +$168M 0.27% 93
2017
Q3 		$10.8M Buy
77,110
+24,882
+48% +$3.38M 0.03% 295
2017
Q2 		$6.36M Hold
52,228
– – 0.02% 381
2017
Q1 		$6.33M Hold
52,228
– – 0.02% 381
2016
Q4 		$6.39M Buy
52,228
+11,290
+28% +$1.38M 0.02% 368
2016
Q3 		$5.02M Sell
40,938
-449
-1% -$57.8K 0.02% 415
2016
Q2 		$4.83M Buy
41,387
+97
+0.2% +$13.8K 0.02% 414
2016
Q1 		$5.75M Sell
41,290
-495
-1% -$72.7K 0.02% 380
2015
Q4 		$7.97M Buy
41,785
+9,723
+30% +$1.7M 0.03% 358
2015
Q3 		$5.01M Hold
32,062
– – 0.02% 426
2015
Q2 		$5.8M Buy
32,062
+121
+0.4% +$20.9K 0.02% 437
2015
Q1 		$5.54M Buy
31,941
+1,146
+4% +$207K 0.02% 444
2014
Q4 		$5.7M Buy
30,795
+295
+1% +$54.7K 0.02% 429
2014
Q3 		$5.06M Sell
30,500
-1,434
-4% -$235K 0.02% 450
2014
Q2 		$4.99M Buy
31,934
+481
+2% +$76K 0.02% 456
2014
Q1 		$4.79M Buy
31,453
+953
+3% +$152K 0.02% 463
2013
Q4 		$4.06M Sell
30,500
-54,477
-64% -$6.54M 0.02% 479
2013
Q3 		$9.87M Buy
84,977
+54,477
+179% +$5.98M 0.04% 335
2013
Q2 		$2.81M Buy
+30,500
New +$2.94M 0.01% 513

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi Asset Management US's ALXN Position: Q1 2021 in Review

Amundi Asset Management US reduced its Alexion Pharmaceuticals (ALXN) stake by 67% in Q1 2021, selling an estimated $140M and leaving 454,408 shares worth $69.5M. The position accounts for 0.05% of the portfolio, ranked #344.

Amundi Asset Management US first reported a position in ALXN in Q2 2013 and has held it in 32 quarters since. The position peaked at $213M in Q4 2020. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Amundi Asset Management US held 454,408 shares of Alexion Pharmaceuticals worth $69.5M as of Q1 2021.
  • Amundi Asset Management US sold 906,090 Alexion Pharmaceuticals shares in Q1 2021, an estimated $140M.
  • Alexion Pharmaceuticals made up 0.05% of Amundi Asset Management US's portfolio in Q1 2021, its #344 holding.
  • Amundi Asset Management US first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 32 quarters since.
  • Amundi Asset Management US's Alexion Pharmaceuticals position peaked at $213M in Q4 2020.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.